Unicycive Therapeutics, Inc.(UNCY)Earnings, Financials & Key Ratios
UNCY•NASDAQ
$8.13
$54M mkt cap·Price updated May 6, 2026
AboutUnicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.Show more
- Revenue$0-100.0%
- EBITDA-$32M-54.7%
- Net Income-$37M-20.2%
- EPS (Diluted)-5.60-337.5%
- ROE-2028.11%
- Debt/Equity0.10
- Interest Coverage-452.35-78.6%
UNCY Key Insights
Unicycive Therapeutics, Inc. (UNCY) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Momentum leader: RS Rating 86 (top 14%)
- ✓Healthy dividend yield of 2.0%
✗Weaknesses
- ✗Shares diluted 100.0% in last year
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
UNCY Price & Volume
Unicycive Therapeutics, Inc. (UNCY) stock price & volume — 10-year historical chart
Loading chart...
UNCY Growth Metrics
Unicycive Therapeutics, Inc. (UNCY) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-45.26%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM50.92%
Return on Capital
10 Years-626.45%
5 Years-626.45%
3 Years-875.4%
Last Year-1527.56%
UNCY Recent Earnings
Unicycive Therapeutics, Inc. (UNCY) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 6/12 qtrs (50%)
Q4 2025Latest
Nov 12, 2025EPS
$0.39
Est $0.59
+33.9%
Revenue
—
Q3 2025
Aug 14, 2025EPS
$0.52
Est $0.70
+25.7%
Revenue
—
Q2 2025
Mar 31, 2025EPS
$0.26
Est $0.13
-100.0%
Revenue
—
Q2 2025
Mar 27, 2025EPS
$0.16
Est $0.13
-23.1%
Revenue
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q4 2025Latest | Nov 12, 2025 | $0.39vs $0.59+33.9% | — |
| Q3 2025 | Aug 14, 2025 | $0.52vs $0.70+25.7% | — |
| Q2 2025 | Mar 31, 2025 | $0.26vs $0.13-100.0% | — |
| Q2 2025 | Mar 27, 2025 | $0.16vs $0.13-23.1% | — |
Based on last 12 quarters of dataView full earnings history →
UNCY Peer Comparison
Unicycive Therapeutics, Inc. (UNCY) competitors in Commercial Specialty Pharma — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 ARWR | 11.08B | 79.14 | -6486.89 | 232.58% | 18.54% | 35.64% | 0.73 | |
 CYCN | 14.03M | 3.24 | -2.97 | 3.7% | -170.11% | -39.23% | ||
 RMTI | 31.92M | 0.81 | -32.14 | 21.38% | -7.3% | -14.9% | 0.42 | |
 LPCN | 13.17M | 2.43 | -1.44 | -82.35% | -487.05% | -59.29% | ||
 NKTR | 1.67B | 85.09 | -8.75 | -43.89% | -192.87% | -356.81% | 0.95 | |
 VKTX | 3.74B | 32.28 | -10.12 | -71.31% | 0.00 | |||
 DVAX | 1.82B | 15.50 | 77.50 | 19.36% | -13.13% | -8.13% | 0.43 | |
 HALO | 7.81B | 66.35 | 25.92 | 37.55% | 22.69% | 6.49% |
Compare UNCY vs Peers
Unicycive Therapeutics, Inc. (UNCY) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
UNCY Income Statement
Unicycive Therapeutics, Inc. (UNCY) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 951K | 675K | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | -29.02% | -100% | - |
| Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - | - | - | - |
| Gross Profit | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 951K▲ 0% | 675K▼ 29.0% | 0▼ 100.0% | 0▲ 0% |
| Gross Margin % | - | - | - | - | 100% | 100% | - | - |
| Gross Profit Growth % | - | - | - | - | - | -29.02% | -100% | - |
| Operating Expenses | 952K | 1.96M | 2.02M | 8.98M | 19M | 21.45M | 32.12M | 31.55M |
| OpEx % of Revenue | - | - | - | - | 1998.21% | 3177.63% | - | - |
| Selling, General & Admin | 608K | 1.17M | 1M | 2.9M | 6.57M | 8.55M | 12.1M | 19.38M |
| SG&A % of Revenue | - | - | - | - | 690.54% | 1266.22% | - | - |
| Research & Development | 344K | 795K | 1.01M | 6.08M | 12.44M | 12.9M | 20.01M | 12.17M |
| R&D % of Revenue | - | - | - | - | 1307.68% | 1911.41% | - | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -952K▲ 0% | -1.96M▼ 106.2% | -2.02M▼ 2.9% | -8.98M▼ 344.4% | -18.05M▼ 101.1% | -20.77M▼ 15.1% | -32.12M▼ 54.6% | -31.55M▲ 0% |
| Operating Margin % | - | - | - | - | -1898.21% | -3077.63% | - | - |
| Operating Income Growth % | - | -106.2% | -2.9% | -344.41% | -101.09% | -15.08% | -54.6% | - |
| EBITDA | 0 | 0 | 0 | -8.96M | -17.89M | -20.49M | -31.69M | -31.13M |
| EBITDA Margin % | - | - | - | - | -1881.28% | -3035.56% | - | - |
| EBITDA Growth % | - | - | - | - | -99.59% | -14.53% | -54.66% | -8.23% |
| D&A (Non-Cash Add-back) | 952K | 1.96M | 2.02M | 13K | 161K | 284K | 428K | 428K |
| EBIT | -952K | -2.03M | -2.02M | -9.39M | -18.05M | -30.46M | -36.66M | -21.11M |
| Net Interest Income | 0 | 0 | 0 | -628K | -6K | 533K | 1.19M | 911K |
| Interest Income | 168K | 139K | 244K | 0 | 0 | 615K | 1.26M | 974K |
| Interest Expense | 0 | 139K | 244K | 628K | 6K | 82K | 71K | 63K |
| Other Income/Expense | -168K | -202K | -244K | -1.04M | -6K | -9.77M | -4.61M | -1.86M |
| Pretax Income | -1.12M▲ 0% | -2.17M▼ 93.3% | -2.26M▼ 4.6% | -10.02M▼ 342.4% | -18.06M▼ 80.3% | -30.54M▼ 69.1% | -36.73M▼ 20.2% | -33.41M▲ 0% |
| Pretax Margin % | - | - | - | - | -1898.84% | -4525.04% | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -1.12M▲ 0% | -2.3M▼ 105.7% | -2.51M▼ 8.9% | -10.02M▼ 299.4% | -18.06M▼ 80.3% | -30.54M▼ 69.1% | -36.73M▼ 20.2% | -33.41M▲ 0% |
| Net Margin % | - | - | - | - | -1898.84% | -4525.04% | - | - |
| Net Income Growth % | - | -105.71% | -8.85% | -299.4% | -80.27% | -69.14% | -20.25% | -45.26% |
| Net Income (Continuing) | -1.12M | -2.17M | -2.26M | -10.02M | -18.06M | -30.54M | -36.73M | -33.41M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.14▲ 0% | -0.27▼ 92.9% | -0.16▲ 40.7% | -8.60▼ 5275.0% | -1.20▲ 86.0% | -1.28▼ 6.7% | -5.60▼ 337.5% | -1.85▲ 0% |
| EPS Growth % | - | -92.86% | 40.74% | -5275% | 86.05% | -6.67% | -337.5% | 50.92% |
| EPS (Basic) | -0.14 | -0.27 | -0.16 | -8.60 | -1.20 | -1.28 | -5.60 | - |
| Diluted Shares Outstanding | 794.32K | 847.15K | 1.52M | 1.17M | 1.51M | 2.45M | 6.7M | 18.07M |
| Basic Shares Outstanding | 794.32K | 842.5K | 1.52M | 1.17M | 1.51M | 2.45M | 6.7M | 18.07M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - |
UNCY Balance Sheet
Unicycive Therapeutics, Inc. (UNCY) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 29K | 19K | 204K | 18.41M | 2.64M | 13.4M | 30.95M | 50.29M |
| Cash & Short-Term Investments | 25K | 15K | 0 | 16.58M | 455K | 9.7M | 26.14M | 42.7M |
| Cash Only | 25K | 15K | 0 | 16.58M | 455K | 9.7M | 26.14M | 42.7M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Sales Outstanding | - | - | - | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 4K | 204K | 126K | 159K | 325K | 939K | 7.59M |
| Total Non-Current Assets | 0 | 0 | 200K | 333K | 174K | 792K | 720K | 324K |
| Property, Plant & Equipment | 0 | 0 | 0 | 333K | 174K | 792K | 720K | 324K |
| Fixed Asset Turnover | - | - | - | - | 5.47x | 0.85x | - | 0.00x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 0 | 0 | 200K | 0 | 0 | 0 | 0 | 0 |
| Total Assets | 29K▲ 0% | 19K▼ 34.5% | 204K▲ 973.7% | 18.74M▲ 9088.2% | 2.82M▼ 85.0% | 14.19M▲ 403.6% | 31.67M▲ 123.2% | 50.61M▲ 0% |
| Asset Turnover | - | - | - | - | 0.34x | 0.05x | - | 0.00x |
| Asset Growth % | - | -34.48% | 973.68% | 9088.24% | -84.97% | 403.58% | 123.16% | 74.81% |
| Total Current Liabilities | 1.24M | 903K | 2.88M | 2.1M | 3.28M | 17.53M | 24.12M | 13.13M |
| Accounts Payable | 60K | 322K | 184K | 742K | 846K | 821K | 966K | 957K |
| Days Payables Outstanding | - | - | - | - | - | - | - | - |
| Short-Term Debt | 1.05M | 460K | 2.51M | 29K | 46K | 18K | 92K | 265K |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 0 | 0 | -29K | 0 | 13.13M | 18.94M | 11.91M |
| Current Ratio | 0.02x | 0.02x | 0.07x | 8.75x | 0.81x | 0.76x | 1.28x | 1.28x |
| Quick Ratio | 0.02x | 0.02x | 0.07x | 8.75x | 0.81x | 0.76x | 1.28x | 1.28x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 0 | 0 | 0 | 155K | 0 | 466K | 117K | 0 |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 155K | 0 | 466K | 117K | 117K |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 1.24M | 903K | 2.88M | 2.26M | 3.28M | 18M | 24.24M | 13.13M |
| Total Debt | 1.05M | 460K | 2.51M | 335K | 201K | 811K | 773K | 265K |
| Net Debt | 1.02M | 445K | 2.51M | -16.24M | -254K | -8.89M | -25.37M | -42.43M |
| Debt / Equity | - | - | - | 0.02x | - | - | 0.10x | 0.10x |
| Debt / EBITDA | - | - | - | - | - | - | - | -0.01x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | 1.36x |
| Interest Coverage | - | -14.12x | -8.28x | -14.29x | -3008.67x | -253.34x | -452.35x | -335.02x |
| Total Equity | -1.21M▲ 0% | -884K▲ 26.7% | -2.67M▼ 202.1% | 16.48M▲ 717.1% | -466K▼ 102.8% | -3.81M▼ 717.4% | 7.43M▲ 295.1% | 37.48M▲ 0% |
| Equity Growth % | - | 26.7% | -202.15% | 717.15% | -102.83% | -717.38% | 295.09% | 233.95% |
| Book Value per Share | -1.52 | -1.04 | -1.75 | 14.12 | -0.31 | -1.55 | 1.11 | 2.07 |
| Total Shareholders' Equity | -1.21M | -884K | -2.67M | 16.48M | -466K | -3.81M | 7.43M | 37.48M |
| Common Stock | 34K | 8K | 9K | 15K | 15K | 35K | 114K | 21K |
| Retained Earnings | -1.49M | -3.66M | -5.92M | -15.94M | -34M | -64.54M | -101.27M | -113.16M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
UNCY Cash Flow Statement
Unicycive Therapeutics, Inc. (UNCY) cash flow — operating, investing & free cash flow history
| Line item | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -775K | -1.18M | -1.46M | -5.77M | -15.65M | -18.28M | -28.57M | -28.57M |
| Operating CF Margin % | - | - | - | - | -1645.74% | -2708.59% | - | - |
| Operating CF Growth % | - | -51.74% | -24.06% | -295.27% | -171.39% | -16.82% | -56.29% | -83.1% |
| Net Income | -1.12M | -2.17M | -2.26M | -10.02M | -18.06M | -30.54M | -36.73M | -33.41M |
| Depreciation & Amortization | 0 | 0 | 0 | 13K | 161K | 284K | 428K | 555K |
| Stock-Based Compensation | 0 | 24K | 232K | 966K | 1.05M | 1.77M | 2.35M | 1.13M |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 308K | 660K | 739K | 3.38M | 21K | 10.3M | 5.8M | 4.08M |
| Working Capital Changes | 6K | 305K | -166K | -105K | 1.18M | -93K | -427K | -2.19M |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 31K | 308K | -68K | 1.24M | 1.27M | 1.28M | 790K | 280K |
| Cash from Investing | 0 | 0 | 0 | -29K | -2K | -12K | -72K | -46K |
| Capital Expenditures | 0 | 0 | 0 | -29K | -2K | -12K | -72K | -46K |
| CapEx % of Revenue | - | - | - | - | 0.21% | 1.78% | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 800K | 1.17M | 1.44M | 22.38M | -471K | 27.54M | 45.09M | 40.23M |
| Debt Issued (Net) | 0 | 0 | 1.42M | -15K | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 0 | 1000K | 141K | 1000K | 11K | 1000K | 1000K | 3.52M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | -1.09M | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 800K | 0 | -117K | 119K | -482K | -2.65M | -4.5M | -67K |
| Net Change in Cash | 25K▲ 0% | -10K▼ 140.0% | -15K▼ 50.0% | 16.58M▲ 110626.7% | -16.12M▼ 197.3% | 9.25M▲ 157.3% | 16.44M▲ 77.8% | 10.35M▲ 0% |
| Free Cash Flow | -775K▲ 0% | -1.18M▼ 51.7% | -1.46M▼ 24.1% | -5.8M▼ 297.3% | -15.65M▼ 170.1% | -18.3M▼ 16.9% | -28.65M▼ 56.6% | -29.88M▲ 0% |
| FCF Margin % | - | - | - | - | -1645.95% | -2710.37% | - | - |
| FCF Growth % | - | -51.74% | -24.06% | -297.26% | -170.07% | -16.88% | -56.58% | -12.68% |
| FCF per Share | -0.98 | -1.39 | -0.96 | -4.96 | -10.40 | -7.46 | -4.28 | -4.28 |
| FCF Conversion (FCF/Net Income) | 0.69x | 0.51x | 0.58x | 0.58x | 0.87x | 0.60x | 0.78x | 0.89x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 24K | 0 | 3K |
| Taxes Paid | 0 | 2K | 1K | 0 | 0 | 0 | 0 | 0 |
UNCY Key Ratios
Unicycive Therapeutics, Inc. (UNCY) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | - | -145.04% | -225.47% | - | -2028.11% | -89.15% |
| Return on Invested Capital (ROIC) | - | - | -16223.49% | - | - | - | 262.13% |
| Gross Margin | - | - | - | 100% | 100% | - | - |
| Net Margin | - | - | - | -1898.84% | -4525.04% | - | - |
| Debt / Equity | - | - | 0.02x | - | - | 0.10x | 0.10x |
| Interest Coverage | -14.12x | -8.28x | -14.29x | -3008.67x | -253.34x | -452.35x | -335.02x |
| FCF Conversion | 0.51x | 0.58x | 0.58x | 0.87x | 0.60x | 0.78x | 0.89x |
| Revenue Growth | - | - | - | - | -29.02% | -100% | - |
UNCY Frequently Asked Questions
Unicycive Therapeutics, Inc. (UNCY) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Unicycive Therapeutics, Inc. (UNCY) saw revenue decline by 100.0% over the past year.
Unicycive Therapeutics, Inc. (UNCY) reported a net loss of $33.4M for fiscal year 2024.
Dividend & Returns
Yes, Unicycive Therapeutics, Inc. (UNCY) pays a dividend with a yield of 2.01%. This makes it attractive for income-focused investors.
Unicycive Therapeutics, Inc. (UNCY) has a return on equity (ROE) of -2028.1%. Negative ROE indicates the company is unprofitable.
Unicycive Therapeutics, Inc. (UNCY) had negative free cash flow of $29.9M in fiscal year 2024, likely due to heavy capital investments.
Explore More UNCY
Unicycive Therapeutics, Inc. (UNCY) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates